Literature DB >> 34826107

Epstein-Barr virus-related lymphoproliferative disorders in T-cell repleted haploidentical transplantation with post-transplant cyclophosphamide.

Vedat Uygun1, Nazan Özsan2, Hayriye Daloğlu3, Seda Öztürkmen4, Koray Yalçın5, Gülsün Karasu6, Akif Yeşilipek4.   

Abstract

EBV-associated lymphoproliferative disorders (LPDs) are common in hematopoietic stem cell transplantation (HSCT) with T-cell-depleted grafts, but are extremely rare in HSCT patients with T-cell-replete grafts with post-transplant cyclophosphamide (PTCy). Here we present the cases of two pediatric patients who developed EBV-related LPD after T-cell-replete haplo-HSCT with PTCy. One of these is the first reported case of EBV-positive mucocutaneous ulcer (EBVMCU) developing after PTCy. EBV-related diseases are rare in T-cell-replete haplo-HSCT patients with PTCy. However, in patients with risk factors, it is reasonable to screen for EBV viremia for LPD.
© 2021. Japanese Society of Hematology.

Entities:  

Keywords:  EBV-positive mucocutaneous ulcer; Epstein–Barr virus; Lymphoproliferative disorder; Post-transplant cyclophosphamide

Mesh:

Substances:

Year:  2021        PMID: 34826107     DOI: 10.1007/s12185-021-03267-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  14 in total

1.  High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis.

Authors:  Maria Queralt Salas; Shruti Prem; Mats Remberger; Wilson Lam; Dennis Dong Hwan Kim; Fotios Vasilios Michelis; Zeyad Al-Shaibani; Armin Gerbitz; Jeffrey Howard Lipton; Auro Viswabandya; Rajat Kumar; Deepali Kumar; Jonas Mattsson; Arjun Datt Law
Journal:  Leuk Lymphoma       Date:  2020-07-25

2.  A case of Epstein Barr virus-related post-transplant lymphoproliferative disorder after haploidentical allogeneic stem cell transplantation using post-transplantation cyclophosphamide.

Authors:  Cindy Lynn Hickey; Rizwan Romee; Sarah Nikiforow; David Dorfman; Michael Mazzeo; John Koreth
Journal:  Haematologica       Date:  2020-04-02       Impact factor: 9.941

3.  EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide.

Authors:  Toshiki Terao; Takafumi Tsushima; Ami Fukumoto; Ayumi Kuzume; Daisuke Miura; Kentaro Narita; Masami Takeuchi; Kosei Matsue
Journal:  Int J Hematol       Date:  2021-03-06       Impact factor: 2.490

4.  Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.

Authors:  Amy E DeZern; Marianna Zahurak; Heather Symons; Kenneth Cooke; Richard J Jones; Robert A Brodsky
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-21       Impact factor: 5.742

5.  Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.

Authors:  Ayumi Fujimoto; Nobuhiro Hiramoto; Satoshi Yamasaki; Yoshihiro Inamoto; Naoyuki Uchida; Tetsuo Maeda; Takehiko Mori; Yoshinobu Kanda; Tadakazu Kondo; Souichi Shiratori; Shigesaburo Miyakoshi; Ken Ishiyama; Kazuhiro Ikegame; Yoshiko Matsuhashi; Junji Tanaka; Tatsuo Ichinohe; Yoshiko Atsuta; Masao Ogata; Ritsuro Suzuki
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-20       Impact factor: 5.742

6.  EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression.

Authors:  Stefan D Dojcinov; Girish Venkataraman; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

7.  Haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide in high-risk children: A single-center study.

Authors:  Vedat Uygun; Gülsün Karasu; Hayriye Daloğlu; Seda Öztürkmen; Suar Çakı Kılıç; Volkan Hazar; Akif Yeşilipek
Journal:  Pediatr Transplant       Date:  2019-07-06

8.  Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.

Authors:  Jennifer A Kanakry; Yvette L Kasamon; Javier Bolaños-Meade; Ivan M Borrello; Robert A Brodsky; Ephraim J Fuchs; Nilanjan Ghosh; Douglas E Gladstone; Christopher D Gocke; Carol Ann Huff; Christopher G Kanakry; Leo Luznik; William Matsui; Huzefa J Mogri; Lode J Swinnen; Heather J Symons; Richard J Jones; Richard F Ambinder
Journal:  Biol Blood Marrow Transplant       Date:  2013-07-18       Impact factor: 5.742

9.  Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

Authors:  Jennifer Clay; Austin G Kulasekararaj; Victoria Potter; Francesco Grimaldi; Donal McLornan; Kavita Raj; Hugues de Lavallade; Michelle Kenyon; Antonio Pagliuca; Ghulam J Mufti; Judith C W Marsh
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742

10.  Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.

Authors:  Christelle Retière; Catherine Willem; Thierry Guillaume; Henri Vié; Laetitia Gautreau-Rolland; Emmanuel Scotet; Xavier Saulquin; Katia Gagne; Marie C Béné; Berthe-Marie Imbert; Beatrice Clemenceau; Pierre Peterlin; Alice Garnier; Patrice Chevallier
Journal:  Oncotarget       Date:  2018-01-27
View more
  1 in total

Review 1.  Co-Occurrence of EBV-Positive Mucocutaneous Ulcer (EBV-MCU) and CLL/SLL in the Head and Neck Region.

Authors:  Patricia Bott; Ilske Oschlies; Andreas Radeloff; Maureen Loewenthal
Journal:  Curr Oncol       Date:  2022-04-15       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.